The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Interleukin‐6 predicts recurrence and survival among head and neck cancer patients
Open accessAbstract
BACKGROUND.: Increased pretreatment serum interleukin (IL)‐6 levels among patients with head and neck squamous cell carcinoma (HNSCC) have been shown to correlate with poor prognosis, but sample sizes in prior studies have been small and thus unable to control for other known prognostic variables. METHODS.: A longitudinal, prospective cohort study determined the correlation between pretreatment serum IL‐6 levels, and tumor recurrence and all‐cause survival in a large population (N = 444) of previously untreated HNSCC patients. Control variables included age, sex, smoking, cancer site and stage, and comorbidities. Kaplan‐Meier plots and univariate and multivariate Cox proportional hazards models were used to study the association between IL‐6 levels, control variables, and time to recurrence and survival. RESULTS.: The median serum IL‐6 level was 13 pg/mL (range, 0‐453). The 2‐year recurrence rate was 35.2% (standard error, 2.67%). The 2‐year death rate was 26.5% (standard error, 2.26%). Multivariate analyses showed that serum IL‐6 levels independently predicted recurrence at significant levels [hazard ratio (HR) = 1.32; 95% confidence interval (CI), 1.11 to 1.58; P = .002] as did cancer site (oral/sinus). Serum IL‐6 level was also a significant independent predictor of poor survival (HR = 1.22; 95% CI, 1.02 to 1.46; P = .03), as were older age, smoking, cancer site (oral/sinus), higher cancer stage, and comorbidities. CONCLUSIONS.: Pretreatment serum IL‐6 could be a valuable biomarker for predicting recurrence and overall survival among HNSCC patients. Using IL‐6 as a biomarker for recurrence and survival may allow for earlier identification and treatment of disease relapse. Cancer 2008. © 2008 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,775
American Joint Committee on Cancer (2002) · Springer eBooks · doi:10.1007/978-1-4757-3656-4 · Cited by 6,379
Interleukin-6 in Biology and Medicine
Akira, S., Taga, T., & Kishimoto, T. (1993) · Advances in Immunology · doi:10.1016/s0065-2776(08)60532-5 · Cited by 1,389
Prognostic Importance of Comorbidity in a Hospital-Based Cancer Registry
Piccirillo, J. F. (2004) · JAMA · doi:10.1001/jama.291.20.2441 · Cited by 1,205
Biological and clinical aspects of interleukin 6
Hirano, T., Akira, S., Taga, T., & Kishimoto, T. (1990) · Immunology Today · doi:10.1016/0167-5699(90)90173-7 · Cited by 1,066
Grandis, J. R., Drenning, S. D., Zeng, Q., Watkins, S. C., Melhem, M. F., Endo, S., Johnson, D. E., Huang, L., He, Y., & Kim, J. D. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.8.4227 · Cited by 588
IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation
Park, S.-J., Nakagawa, T., Kitamura, H., Atsumi, T., Kamon, H., Sawa, S.-I., Kamimura, D., Ueda, N., Iwakura, Y., Ishihara, K., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.3844 · Cited by 519
Grandis, J. R., Drenning, S. D., Chakraborty, A., Zhou, M. Y., Zeng, Q., Pitt, A. S., & Tweardy, D. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3785 · Cited by 507
Le, J., & Vilček, J. (1990) · Pathology Reviews • 1990 · doi:10.1007/978-1-4612-0485-5_7 · Cited by 474
St. John, M. A. R., Li, Y., Zhou, X., Denny, P., Ho, C.-M., Montemagno, C., Shi, W., Qi, F., Wu, B., Sinha, U., et al. (2004) · Archives of Otolaryngology–Head & Neck Surgery · doi:10.1001/archotol.130.8.929 · Cited by 422
Self-citationSerum interleukin 6 as a prognostic factor in patients with prostate cancer.
Nakashima, J., Tachibana, M., Horiguchi, Y., Oya, M., Ohigashi, T., Asakura, H., & Murai, M. (2000) · PubMed · Cited by 351
Zhang, G.-J., & Adachi, I. (1999) · PubMed · Cited by 306
Cytokines and the Hepatic Acute-Phase Response
Ramadori, G., & Christ, B. (1999) · Seminars in Liver Disease · doi:10.1055/s-2007-1007106 · Cited by 299
Sex Differences in Mortality Rate
Owens, I. P. F. (2002) · Science · doi:10.1126/science.1076813 · Cited by 279
(2003) · PubMed · Cited by 272
Alvarez, J. V., Greulich, H., Sellers, W. R., Meyerson, M., & Frank, D. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3757 · Cited by 240
Activation of STAT3 is a marker of poor prognosis in human colorectal cancer
Kusaba, T., Nakayama, T., Yamazumi, K., Yakata, Y., Yoshizaki, A., Inoue, K., Nagayasu, T., & Sekine, I. (2006) · Oncology Reports · doi:10.3892/or.15.6.1445 · Cited by 238
Plante, M., Rubin, S. C., Wong, G. Y., Federici, M. G., Finstad, C. L., & Gastl, G. A. (1994) · Cancer · doi:10.1002/1097-0142(19940401)73:7<1882::aid-cncr2820730718>3.0.co;2-r · Cited by 173
Klampfer, L. (2006) · Current Cancer Drug Targets · doi:10.2174/156800906776056491 · Cited by 171
Marcus, B., Arenberg, D., Lee, J., Kleer, C., Chepeha, D. B., Schmalbach, C. E., Islam, M., Paul, S., Pan, Q., Hanash, S., et al. (2004) · Cancer · doi:10.1002/cncr.20701 · Cited by 163
Self-citationSerum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma.
Riedel, F., Zaiss, I., Herzog, D., Götte, K., Naim, R., & Hörmann, K. (2005) · PubMed · Cited by 162
Leibovici, D., Grossman, H. B., Dinney, C. P., Millikan, R. E., Lerner, S., Wang, Y., Gu, J., Dong, Q., & Wu, X. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.598 · Cited by 160
Serum interleukin-6 levels reflect disease status of gastric cancer.
Wu, C.-H., Wang, S. R., Chao, M. F., Wu, T., Lui, W. Y., Peng, F., & W, C. (1996) · PubMed · Cited by 139
Epidermal Growth Factor Receptor–Mediated Stat3 Signaling Blocks Apoptosis in Head and Neck Cancer
Grandis, J. R., Zeng, Q., & Drenning, S. D. (2000) · The Laryngoscope · doi:10.1097/00005537-200005000-00016 · Cited by 125
Schutter, H. D., Landuyt, W., Verbeken, E. K., Goethals, L., Hermans, R., & Nuyts, S. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-42 · Cited by 117
Interleukin-6 in Renal Cell Carcinoma
Tsukamoto, T., Kumamoto, Y., Miyao, N., Masumori, N., Takahashi, A., & Yanase, M. (1992) · The Journal of Urology · doi:10.1016/s0022-5347(17)37026-x · Cited by 113
Pytynia, K. B., Grant, J. R., Etzel, C. J., Roberts, D. B., Wei, Q., & Sturgis, E. M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.133 · Cited by 91
Woods, K. V., El‐Naggar, A. K., Clayman, G. L., & Grimm, E. A. (1998) · PubMed · Cited by 89
Tanner, J. E., & Tosato, G. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115283 · Cited by 89
INTERLEUKIN-6 POLYMORPHISM IS ASSOCIATED WITH MORE AGGRESSIVE PROSTATE CANCER
Tan, D., Wu, X., Hou, M., Lee, S. O. K., Lou, W., Wang, J., JANARTHAN, B., Nallapareddy, S., Trump, D. L., & Gao, A. C. (2005) · The Journal of Urology · doi:10.1097/01.ju.0000168723.42824.40 · Cited by 67
Yin, W., Cheepala, S., Roberts, J. N., Chan, K. S., DiGiovanni, J., & Clifford, J. L. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-15 · Cited by 58
HYPOXIA, BUT NOT REOXYGENATION, INDUCES INTERLEUKIN 6 GENE EXPRESSION THROUGH NF-??B ACTIVATION1
Muraoka, K., Shimizu, K., Sun, X., Zhang, Y. K., Tani, T., Hashimoto, T., Yagi, M., Miyazaki, I., & Yamamoto, K.-I. (1997) · Transplantation · doi:10.1097/00007890-199702150-00023 · Cited by 51
Interleukin-6 and acute-phase proteins in head and neck cancer
Gallo, O., Gori, A. M., Attanasio, M., et al. (1995) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/bf00178104 · Cited by 49
Thomas, G. R., Chen, Z., Leukinova, E., Waes, C. V., & Wen, J. (2003) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0433-4 · Cited by 49
IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation
朴, 星. (2005) · Cited by 38
de Luis, D. A., Izaola, O., Cuéllar, L., Terroba, M. C., Arranz, M., Fernández, N., & Aller, R. (2003) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1601512 · Cited by 34
de van der Schueren, M. A. E., Blomberg, B. M. E. V., Kuik, D. J., Scholten, P. E. T., Siroen, M. P. C., Snow, G. B., Quak, J. J., & van Leeuwen, P. A. M. (2000) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607100024006329 · Cited by 30
Interleukin-1 beta and interleukin-6 release by peripheral blood monocytes in head and neck cancer
Gallo, O., Gori, A. M., Attanasio, M., Martini, F., Giusti, B., Boddi, M., Gallina, E., Fini, O., & Abbate, R. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.371 · Cited by 27
Cited by
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110
Cytokines in Inflammatory Disease
Kany, S., Vollrath, J. T., & Relja, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236008 · Cited by 1,971
Immunology and Immunotherapy of Head and Neck Cancer
Ferris, R. L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.1509 · Cited by 668
Yadav, A., Kumar, B., Datta, J., Teknos, T. N., & Kumar, P. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0271 · Cited by 503
Self-citationRole of Salivary Biomarkers in Oral Cancer Detection
(2018) · Advances in Clinical Chemistry · doi:10.1016/bs.acc.2018.05.002 · Cited by 286
Metadata
- Authors
- Duffy, S. A., Taylor, J. M. G., Terrell, J. E., Islam, M., Li, Y., Fowler, K. E., Wolf, G. T., & Teknos, T. N.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2008-06-05
- Volume
- 113
- Issue
- 4
- Pages
- 750-757
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2113640115
- Cited by
- 330
- References
- 39
- FWCI
- 17.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.